|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **CON** | **CD** | **UC** |
| **Number** |  | 33 | 11 | 10 |
| **Age (Ø, range)** |  | 27 (22-44) | 42 (22-70) | 47 (25-67) |
| **Female [%]** |  | 63.0 | 54.5 | 40.0 |
| **HBI (Ø, range)** |  |  | 3.3 (0-10) |  |
| **Mayo c.s. (Ø, range)** |  |  |  | 1.4 (0-4) |
| **Therapy [%]** | *Aminosalisylates* |  | 18.2 | 60.0 |
| *Steroids* |  | 9.1 | 20.0 |
| *Immunosup-pressants* |  | 0.0 | 0.0 |
| *Anti-TNF antibodies* |  | 63.6 | 80.0 |
| *Vedolizumab* |  | 0.0 | 0.0 |
| *Ustekinumab* |  | 36.4 | 20.0 |
| **Disease localization [%]** |  |  | L1: 0.0 | E1: 11.1 |
|  |  | L2: 27.3 | E2: 22.2 |
|  |  | L3: 45.4 | E3: 66.7 |
|  |  | L4: 0.0 |  |
|  |  | L4+: 27.3 |  |

**Supplementary Table S1: Summary of patient characteristics in total**